Optimizing growth hormone dosing in children with idiopathic short stature.
In the last 2 decades, recombinant human growth hormone (rhGH) therapy for children with idiopathic short stature (ISS) has demonstrated varying degrees of efficacy. Based on prediction models for this population developed from registry databases and extensive clinical experience, these differences have been attributed to age at diagnosis, dose of rhGH, parental height, treatment compliance, GH sensitivity, effectiveness of GH receptors, potency of the postreceptor signaling cascade, insulin-like growth factor I transcriptional and translational efficiency and epiphyseal responsiveness. Although there are no universally accepted biochemical criteria for determining when to initiate GH therapy for children with ISS, both molecular and biochemical factors may contribute to the success of therapy and play a significant role to maximize adult height.